4558
CHUKYO IYAKUHIN CO.,LTD.
中京医薬品
- Industry
- Pharmaceutical
- Market
- Standard
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Mar 2022
5,356,255
Mar 2023
5,692,647
Mar 2024
6,124,622
Mar 2025
6,306,646
Mar 2026
6,569,307
Operating profit(thousand JPY)
Mar 2022
64,313
Mar 2023
59,683
Mar 2024
128,271
Mar 2025
106,030
Mar 2026
127,424
Operating profit margin(%)
Mar 2022
1.2
Mar 2023
1.05
Mar 2024
2.09
Mar 2025
1.68
Mar 2026
1.94
Profit before tax(thousand JPY)
Mar 2022
94,485
Mar 2023
77,367
Mar 2024
20,252
Mar 2025
125,786
Mar 2026
118,778
Profit(thousand JPY)
Mar 2022
33,218
Mar 2023
14,487
Mar 2024
-27,318
Mar 2025
45,148
Mar 2026
83,612
Total assets(thousand JPY)
Mar 2022
5,339,285
Mar 2023
5,242,712
Mar 2024
5,082,784
Mar 2025
5,065,254
Mar 2026
5,285,285
Cash and cash equivalents(thousand JPY)
Mar 2022
1,286,092
Mar 2023
944,896
Mar 2024
949,434
Mar 2025
1,077,466
Mar 2026
956,713
Cash flows from operating activities(thousand JPY)
Mar 2022
-222,679
Mar 2023
105,833
Mar 2024
171,853
Mar 2025
31,708
Mar 2026
99,020
Cash flows from investing activities(thousand JPY)
Mar 2022
10,501
Mar 2023
-199,959
Mar 2024
-36,046
Mar 2025
53,355
Mar 2026
-300,901
Cash flows from financing activities(thousand JPY)
Mar 2022
255,784
Mar 2023
-247,069
Mar 2024
-131,269
Mar 2025
42,967
Mar 2026
81,128
Return on equity(%)
Mar 2022
1.31
Mar 2023
0.56
Mar 2024
-1.07
Mar 2025
1.79
Mar 2026
3.28
Equity ratio(%)
Mar 2022
49
Mar 2023
49.3
Mar 2024
49.6
Mar 2025
49.9
Mar 2026
48.8
Earnings per share(JPY per share)
Mar 2022
3.16
Mar 2023
1.36
Mar 2024
-2.57
Mar 2025
4.24
Mar 2026
7.84
Net assets per share(JPY per share)
Mar 2022
246.38
Mar 2023
242.89
Mar 2024
236.95
Mar 2025
236.98
Mar 2026
241.49
Dividend per share(JPY per share)
Mar 2022
5
Mar 2023
5
Mar 2024
5
Mar 2025
5
Mar 2026
5
Payout ratio(%)
Mar 2022
158.23
Mar 2023
367.65
Mar 2024
-
Mar 2025
117.92
Mar 2026
63.78
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.